

Haematologica
HAEMATOL/2015/138388
Version 3

Brentuximab vedotin followed by ABVD +/- radiotherapy in patients with previously untreated Hodgkin lymphoma: final results of a pilot phase II study

Massimo Federico, Stefano Luminari, Cinzia Pellegrini, Francesco Merli, Emanuela Anna Pesce, Stephane Chauvie, Letizia Gandolfi, Isabella Capodanno, Massimiliano Salati, Lisa Argnani, and Pier Luigi Zinzani

Disclosures: Consultant or Advisory Role: Massimo Federico: Millennium Pharmaceuticals, Inc; Stefano Luminari: Roche, Celgene, Teva. Honoraria: Stefano Luminari: Pfizer.

Contributions: All authors equally contributed in conception and design of research, manuscript writing and final approval of manuscript. MF, SL, FM, PLZ, EAP performed data analysis. EAP, MS, LA collected data. MF supervised the study